Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 705

recruiting
3 972
countries
28
conditions
2 104

10 284 trials match your criteria

Bladder transitional cell carcinoma

Not recruiting

Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab

Soft tissue sarcoma

Not recruiting

Study on L19TNF and Doxorubicin for Patients with Advanced or Metastatic Soft Tissue Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Onfekafusp Alfa

Fragile X syndrome

Not recruiting

Study on Long-Term Safety of ZYN002 Gel for Children, Adolescents, and Young Adults with Fragile X Syndrome

InvestigationalNo placebo
Countries:IrelandIreland
  • Participants:0–17 years · 18–64 years
  • Substances:Cannabidiol

Biliary neoplasm+1

Not recruiting

Study on Rilvegostomig and Chemotherapy for Patients with Biliary Tract Cancer After Surgery

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Acute graft versus host disease in intestine

Not recruiting

Study on the Safety and Effectiveness of Apraglutide for Patients with Steroid-Resistant Gastrointestinal Acute Graft Versus Host Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Apraglutide

Adenocarcinoma gastric+1

Not recruiting

Study of Zolbetuximab Alone and with Drug Combination for Patients with Advanced Stomach or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil

Latent autoimmune diabetes in adults

Not recruiting

Study on Latent Autoimmune Diabetes in Adults (LADA) Patients: Evaluating Diabetes Status 3 Years After Treatment with Glutamate Decarboxylase 2

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Glutamate decarboxylase 2, human, recombinant

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Amivantamab and Capmatinib for Patients with Unresectable Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab

Thyroid cancer+18

Not recruiting

Study of JK08, Pembrolizumab, and Lenvatinib for Patients with Advanced or Metastatic Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib

Duchenne muscular dystrophy gene carrier

Not recruiting

Study to Determine the Best Dose of Vesleteplirsen for Patients with Duchenne Muscular Dystrophy Suitable for Exon 51-Skipping Treatment

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Vesleteplirsen

Epilepsy

Not recruiting

Study on the Effectiveness and Safety of Perampanel for Children with Epilepsy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Perampanel

B-cell lymphoma+1

Not recruiting

Study of Axi-Cel, Fludarabine Phosphate, and Cyclophosphamide for Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.